Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]

Stay Informed Latest News Recent news about Osteoporosis and Osteoporosis Canada. VIEW Position Statements Osteoporosis Canada’s rapid response team, made up of members of the Scientific Advisory Council, creates position statements […]

Osteoporosis Canada (OC) is excited to announce the upcoming launch of the OC FLS Registry. The OC FLS Registry will be an online map profiling FLS programs across Canada, which meet OC’s Essential […]

Latest News Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture April 3, 2024 Amgen Canada has […]

Marinade time: 2 hrs Grill time: 25 mins Marinade time: 2 hrs Grill time: 25 mins Marinade time: 2 hrs Grill time: 25 mins Ingredients   Preparation Note: If you […]

VITAMIN D IS VERY IMPORTANT TO OUR BONE HEALTH When taken in the appropriate amount, vitamin D decreases our risk of falling and breaking bones. It is very common to […]

2010 Clinical Practice Guidelines Additional Osteoporosis Guidelines Resources 2010 Clinical Practice Guidelines Access the CMAJ publication. READ THE PUBLICATION 2010 Clinical Practice Guidelines Technical Report Access the Technical Report. READ […]

Now that spring is officially here, many of us are excitedly waiting until we can get outside and into our balcony or backyard gardens. The pandemic has made outdoor interests […]